Communicated by Maria Rita Passos-BuenoDiamond-Blackfan anemia (DBA) is an inherited disease characterized by pure erythroid aplasia. Thirty percent (30%) of patients display malformations, especially of the hands, face, heart, and urogenital tract. DBA has an autosomal dominant pattern of inheritance. De novo mutations are common and familial cases display wide clinical heterogeneity. Twenty-five percent (25%) of patients carry a mutation in the ribosomal protein (RP) S19 gene, whereas mutations in RPS24, RPS17, RPL35A, RPL11, and RPL5 are rare. These genes encode for structural proteins of the ribosome. A link between ribosomal functions and erythroid aplasia is apparent in DBA, but its etiology is not clear. Most authors agree that a defect in protein synthesis in a rapidly proliferating tissue, such as the erythroid bone marrow, may explain the defective erythropoiesis. A total of 77 RPS19 mutations have been described. Most are whole gene deletions, translocations, or truncating mutations (nonsense or frameshift), suggesting that haploinsufficiency is the basis of DBA pathology. A total of 22 missense mutations have also been described and several works have provided in vitro functional data for the mutant proteins. This review looks at the data on all these mutations, proposes a functional classification, and describes six new mutations. It is shown that patients with RPS19 mutations display a poorer response to steroids and a worse long-term prognosis compared to other DBA patients. Hum Mutat 29(7), [911][912][913][914][915][916][917][918][919][920] 2008.

BackgroundDiamond-Blackfan anemia is a rare, pure red blood cell aplasia of childhood due to an intrinsic defect in erythropoietic progenitors. About 40% of patients display various malformations. Anemia is corrected by steroid treatment in more than 50% of cases; nonresponders need chronic transfusions or stem cell transplantation. Defects in the RPS19 gene, encoding the ribosomal protein S19, are the main known cause of DiamondBlackfan anemia and account for more than 25% of cases. Mutations in RPS24, RPS17, and RPL35A described in a minority of patients show that Diamond-Blackfan anemia is a disorder of ribosome biogenesis. Two new genes (RPL5, RPL11), encoding for ribosomal proteins of the large subunit, have been reported to be involved in a considerable percentage of patients. Design and MethodsIn this genotype-phenotype analysis we screened the coding sequence and intron-exon boundaries of RPS14, RPS16, RPS24, RPL5, RPL11, and RPL35A in 92 Italian patients with Diamond-Blackfan anemia who were negative for RPS19 mutations. ResultsAbout 20% of the patients screened had mutations in RPL5 or RPL11, and only 1.6% in RPS24. All but three mutations that we report here are new mutations. No mutations were found in RPS14, RPS16, or RPL35A. Remarkably, we observed a higher percentage of somatic malformations in patients with RPL5 and RPL11 mutations. A close association was evident between RPL5 mutations and craniofacial malformations, and between hand malformations and RPL11 mutations. ConclusionsMutations in four ribosomal proteins account for around 50% of all cases of DiamondBlackfan anemia in Italian patients. Genotype-phenotype data suggest that mutation screening should begin with RPL5 and RPL11 in patients with Diamond-Blackfan anemia with malformations.Key words: red cells, bone marrow failure, anemia, DBA, ribosomal proteins.Citation: Quarello P, Garelli E, Carando A, Brusco A, Calabrese R, Dufour C, Longoni D, Misuraca A, Vinti L, Aspesi A, Biondini L, Loreni F, Dianzani I, and Ramenghi U. Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations Haematologica. 2010; 95:206-213. doi:10.3324/haematol.2009

Mutations in the hematopoietic transcription factor GATA-1 alter the proliferation/differentiation of hemopoietic progenitors. Mutations in exon 2 interfere with the synthesis of the full-length isoform of GATA-1 and lead to the production of a shortened isoform, GATA-1s. These mutations have been found in patients with Diamond-Blackfan anemia (DBA), a congenital erythroid aplasia typically caused by mutations in genes encoding ribosomal proteins. We sequenced GATA-1 in 23 patients that were negative for mutations in the most frequently mutated DBA genes. One patient showed a c.2T > C mutation in the initiation codon leading to the loss of the full-length GATA-1 isoform.

Mutations in ribosomal proteins RPS19, RPS24 and RPS17 have been reported in DiamondBlackfan Anemia (DBA), an autosomal dominant disease characterised by pure red cell aplasia. DBA is the prototype of ribosomapathies: a protein synthesis defect in a tissue with a high cellular turnover is considered the cause of the erythroid progenitor failure. We have created the Diamond-Blackfan Anemia mutation database to curate and record DBA gene mutations, together with their functional consequences and clinical phenotypes. This locusspecific resource is open to future submissions and is available online (http://www.dbagenes.unito.it). It is founded on the Leiden Open (source) Variation Database (LOVD) system and includes data from sequence and structure analysis tools, genomic database resources and published reports. It lists all identified variants and background genomic information. Phenotypic data are accessed by selecting a particular mutation. The database includes 219 unique variants of which 86 are disease-causing mutations. The database will be supplemented with other DBA genes as soon as they are reported and their mutations are identified and it should be of assistance to clinicians and investigators involved in DBA research and care.© 2008 Wiley-Liss, Inc.KEY WORDS: Diamond-Blackfan Anemia, ribosomal protein, erythropoiesis, ribosome biogenesis. INTRODUCTIONDiamond-Blackfan anemia (DBA; MIM# 105650) is a pure red cell aplasia of childhood with an incidence ranging from 5 to 10 cases per million live births in Europe [Campagnoli et al., 2004]. Its main clinical features are normochromic and macrocytic anemia, reticulocytopenia and hypoplasia of erythroid progenitors in the bone marrow, whereas other hematopoietic lineages are usually normal [Campagnoli et al., 2004]. About 30% of patients display somatic abnormalities, involving the upper limbs, head, neck, the urogenital and cardiovascular systems, along with growth retardation. Patients have an increased risk of malignancies [Campagnoli et al., 2004;Lipton et al., 2001]. Management begins with corticosteroids, though the response is variable. Non-responders require multiple blood transfusions. Allogeneic bone marrow or stem cells transplantation is the only curative treatment at present [Roy et al., 2005;Lipton et al., 2006].Ribosomal protein (RP) S19 was the only gene associated with DBA for several years. It is mutated in 25% of patients with either sporadic or familial DBA, always in heterozygosity [Draptchinskaia et al., 1999;Campagnoli et al., 2008]. Mutations in RPS24 have been identified in 3/215 (~2%) DBA probands [Gazda et al., 2006] RPS17 mutation was reported in 1/24 [Cmejla et al., 2007]. Mutations in RPL35A [Farrar et al., 2007], RPL11 and RPL5 have been described, but not yet published in extenso. DBA is thus the only known human disease caused by an RP deficiency and is the prototype of ribosomapathies [Luzzatto and Karadimitris, 1998].The RPS19 gene (MIM# 603474) maps on locus 19q13.2, comprises six exons and spans 11 kb. The first exon (3...

No abstract